EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

3‐Month Melatonin Supplementation to Reduce Brain Oxidative Stress and Improve Sleep in Mild Cognitive Impairment: A Randomised Controlled Feasibility Trial

Zoe Menczel Schrire, Craig L Phillips, Shantel L Duffy, Nathaniel S Marshall, Loren Mowszowski, Haley M La Monica, Lachlan Stranks, Christopher J Gordon, Julia L Chapman, Bandana Saini, Sharon L Naismith, Ronald R Grunstein und 1 weitere

Journal of Pineal Research · 2024

DOI: 10.1111/jpi.70019 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Pineal Research, 2024. Verfasst von Zoe Menczel Schrire und 12 weiteren Autor:innen. Beteiligte Einrichtung: Healthy Brain Ageing Program, Brain and Mind Centre, School of Psychology, The University of Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Melatonin, Cognitive Dysfunction, Oxidative Stress, Brain. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: This research was supported by the National Health and Medical Research Council, National Heart Foundation of Australia., National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Melatonin has multiple proposed therapeutic benefits including antioxidant properties, circadian rhythm synchronisation and sleep promotion. Since these areas are also recognised risk factors for dementia, melatonin has been hypothesised to slow cognitive decline in older adults. Participants with Mild Cognitive Impairment (MCI) were recruited from the community for a 12‐week randomised placebo‐controlled parallel, feasibility trial of 25 mg oral melatonin nightly. Primary outcomes were feasibility, acceptability, and tolerability. Secondary efficacy outcomes were brain oxidative stress, cognition, mood, and sleep at 12 weeks. Forty participants (mean [SD] age = 68.2 [4.7] years; 19 female) were randomised. Feasibility, defined as those who met eligibility criteria, was 42/389, 11%. Acceptability, determined by the proportion of eligible people who agreed to be randomised, was 40/44, 91%. Tolerability, determined by adherence to the nightly melatonin and completion of the main secondary outcome (Magnetic Resonance Spectroscopy scan) was over the pre‐defined 80% threshold for all participants. The study was not powered to detect effectiveness. Accordingly, there were no significant differences between melatonin and placebo interventions in any of the secondary outcomes. The protocol was developed, and successfully implemented, with the planned number of eligible participants recruited. All participants were able to complete all aspects of the trial, including online visits and assessments, with no differences in adverse events between groups. This is promising for future trials, which should conduct the study with a larger sample size and longer duration to yield necessary efficacy data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelatoninCognitive DysfunctionOxidative StressBrainFeasibility StudiesHumansFemaleAgedMaleMiddle AgedSleepDietary Supplements

Stichwörter der Autor:innen

dementiapreventative medicinesleep medicine

Substanzen

Melatonin

Autor:innen und Institutionen

  • Healthy Brain Ageing Program, Brain and Mind Centre, School of Psychology, The University of Sydney, Sydney, New South Wales, Australia.
  • CIRUS, Centre for Sleep and Chronobiology, The Woolcock Institute of Medical Research, Macquarie University, Sydney, New South Wales, Australia.
  • Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.
  • Department of Health Sciences, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.
  • Allied Health, Research and Strategic Partnerships; Nepean Blue Mountains Local Health District, Penrith, New South Wales, Australia.
  • Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.

Förderung

  • This research was supported by the National Health and Medical Research Council
  • National Heart Foundation of Australia.
  • National Health and Medical Research Council
  • National Heart Foundation of Australia

Zitieren

APA

Menczel Schrire, Z., Phillips, C. L., Duffy, S. L., Marshall, N. S., Mowszowski, L., La Monica, H. M., Stranks, L., Gordon, C. J., Chapman, J. L., Saini, B., Naismith, S. L., Grunstein, R. R., & Hoyos, C. M. (2024). 3‐Month Melatonin Supplementation to Reduce Brain Oxidative Stress and Improve Sleep in Mild Cognitive Impairment: A Randomised Controlled Feasibility Trial. Journal of Pineal Research. https://doi.org/10.1111/jpi.70019

Vancouver

Menczel Schrire Z, Phillips CL, Duffy SL, Marshall NS, Mowszowski L, La Monica HM, et al. 3‐Month Melatonin Supplementation to Reduce Brain Oxidative Stress and Improve Sleep in Mild Cognitive Impairment: A Randomised Controlled Feasibility Trial. Journal of Pineal Research. 2024. doi:10.1111/jpi.70019

BibTeX
@article{MenczelSchrire2024,
  author = {Menczel Schrire, Zoe and Phillips, Craig L and Duffy, Shantel L and Marshall, Nathaniel S and Mowszowski, Loren and La Monica, Haley M and Stranks, Lachlan and Gordon, Christopher J and Chapman, Julia L and Saini, Bandana and Naismith, Sharon L and Grunstein, Ronald R and Hoyos, Camilla M},
  title = {3‐Month Melatonin Supplementation to Reduce Brain Oxidative Stress and Improve Sleep in Mild Cognitive Impairment: A Randomised Controlled Feasibility Trial},
  journal = {Journal of Pineal Research},
  year = {2024},
  doi = {10.1111/jpi.70019}
}
Kostenlos starten →